Skip to main content
OpenTrials
Completed

NCT Number: NCT02683213

Efficacy of Fluoxetine - a Trial in Stroke

The purpose of this study is to investigate whether routine administration of fluoxetine 20mg once daily in the 6 months initiated during the acute stroke improves the patient's functional outcome.

EFFECTS is an investigator lead Sweden-based, multicenter, parallel group, double blind placebo controlled trial with broad entry criteria and follow up at 6 and 12 months.

EFFECTS managed to recruit its anticipated numbers of 1,500 participants between 20th October 2014 and 28th June 2019. Data will be unblinded when the 6-months follow-up is completed, and the primary outcome is due to report on May 2020.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stroke Behavior Behavioral Symptoms Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Depression Nervous System Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Karolinska Institutet

Stockholm, 171 76, Sweden

About this study

Stroke is a serious, life-threatening medical condition that happens when the blood supply to a part of the brain is cut off, usually due to a blood clot (ischemic) or hemorrhage. Symptoms vary according to how much of the brain is affected and where in the brain the stroke occurs but includes paralysis, muscle weakness and speech problems.

A stroke can also have an impact on the sufferers emotions and can lead to anxiety, depression and personality changes. Fluoxetine (otherwise known as Prozac) has been used for many years to treat depression. However, there is evidence to suggest that it may also have other effects of the brain and enhance brain plasticity (the reorganisation of neural pathways in the brain) in a number of different ways.

One small study, for example, has shown that, if taken soon after a stroke, fluoxetine might improve the recovery of arm strength and lead to greater restoration of movement of the limbs.

Adult participants (at least 18 years old) who have had a stroke (either ischemic or hemorrhagic) within the last 2-15 days and still have some residual problems caused by the stroke e.g. weakness, or problems with their speech (speech impairment).

Participants are randomly allocated into one of two groups. Those in group 1 are given fluoxetine capsules for 6 months. Those in group 2 are given a placebo capsules for 6 months.

The participants are contacted after one week of starting their treatment, and then again after one month, to check on their well-being and that they are still taking their allocated caplets. Each participant is asked about any side effects and how much training they have had with e.g. a physiotherapist, occupational- or speech-therapist.

The research team contacts each participant at 3 months to check whether they are still taking the capsules, ask about bad side effects, and about how they are feeling (mood). If all is well, the participant is given enough medication to cover the rest of the study period.

The participant is asked to stop the study medication after 6 months and repeat assessments that they did before they started the study at the local hospital. They are also asked to fill in questionnaires together with their next of kin or carer. These questionnaires are sent to the trial main centre. If needed, they can also be filled in with the help of a trial nurse over the telephone.

The participants are contacted again one month after they have stopped the medication to see how they have progressed.

At 12 months after recruitment, participants are asked to complete the same questionnaires again about how well they have recovered from their stroke and what problems they now have after the stroke e.g. weakness in limbs, memory problems, problems with speech, low mood. These questionnaires can again be completed on paper or by telephone. The researchers then collect data on long-term recovery through national statistics.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent can only be obtained from a patient who according to the trial investigator is mentally capable of decision-making and who, after having received information and got answers to their questions, wants to participate in the trial.
  • Brain imaging is compatible with intra cerebral hemorrhage or ischemic stroke.
  • Randomization can be performed between 2 and 15 days after stroke onset and by the research group at the patient's local/emergency hospital.
  • Persisting focal neurological deficit is present at the time of randomization severe enough to warrant treatment from the physicians and the patient's and relative's perspective.

Exclusion criteria

  • Subarachnoidal hemorrhage except where secondary to a primary intracerebral hemorrhage.
  • Unlikely to be available for follow up for the next 12 months e.g. no fixed home address.
  • Unable to speak Swedish and no close family member available to help with follow up forms.
  • Other life threatening illness (e.g. advanced cancer) that will make 12-month survival unlikely.
  • History of epileptic seizures.
  • History of allergy or contraindications to fluoxetine including: Hepatic impairment (S-ASAT/ALAT > 3 upper normal limit) and renal impairment (S-Creatinine levels > 180 micromol/L).
  • Pregnant or breastfeeding, women of childbearing age not taking contraception. Minimum contraception is an oral contraceptive. An HCG-test is to be made prior randomization and after the end of trial medication.
  • Previous drug overdose or attempted suicide.
  • Already enrolled into a CTIMP.
  • Current or recent (within the last month) depression requiring treatment with an SSRI antidepressant.

Current use of medications which have serious interactions with fluoxetine Use of any mono-amino-oxidase inhibitor (MAOI) during the last 5 weeks. Co-administration of Fluoxetine and a mono-amino-oxidase inhibitor (MAOI) may result in life threatening interactions. Therefore, patients on MAOI are ineligible for the EFFECTS trial. Also, any patient in need of treatment with a MAOI must stop their trial treatment for at least 5 weeks before commencing the MAOI, or to be treated as in-patients by a psychiatrist.

Treatment and study plan

Fluoxetine

Drug

Fluoxetine 20mg once daily for 6 months.

Placebo

Drug

Matching placebo.

Primary outcomes

  1. Functional status, measured with the modified Rankin scale.

    Time frame: 6 months

    The simple modified Rankin scale questionnaire delivered by postal questionnaire, or via interview over the telephone or face to face to determine the modified Rankin scale.

Secondary outcomes

  1. Survival

    Time frame: This will be determined by following patients up for 12 months.

    Survival will be analysed with the Cox proportional hazards model adjusting for the factors included in the minimisation algorithm

  2. Functional status, measured with the modified Rankin scale.

    Time frame: 12 months

    The simple modified Rankin scale questionnaire delivered by postal questionnaire, or via interview over the telephone or face to face to determine the modified Rankin scale. The study will also investigate if the benefits of Fluoxetine remains at 12 months.

  3. Health status measured with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    Health status will be measured with the Stroke Impact Scale

  4. Arm, hand, leg and foot strength assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

    The 8 domains in the Stroke Impact Scale will be used for secondary outcome measures 5 to 13.

  5. Hand function assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

  6. Mobility assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

  7. Communication and understanding assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

  8. Memory and thinking assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

  9. Mood and emotions assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

  10. Daily activities assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

  11. Participation in work, leisure and social activities assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

  12. Overall rating of recovery assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    The Stroke Impact Scale will provide an overall assessment of patient outcome as well as allowing us to assess the effect of treatment on specific outcomes of importance to the patients. The Stroke Impact Scale was developed with input from both patients and caregivers and includes 8 domains (strength, hand function, ADL/IADL, mobility, communication, emotion, memory and thinking, participation) from across the full impairment-participation continuum.

  13. Adverse events/outcomes

    Time frame: At 6 and 12 months

    We will specifically ask for adverse events at each follow-up time (1 week, 1 month, 3 months, 6 months and 12 months), see the outcome 16-24 below. The definition of the SAE is defined according to Good Clinical Practice. We will not register known side effects of fluoxetine, which are listed in the drug's Summary of Product Characteristics. We will not register known problems following stroke, such as pneumonia, deep vein thrombosis etc.

  14. Depression using the Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: At 6 and 12 months

    Depression using the Montgomery-Åsberg Depression Rating Scale (MADRS) and patients scoring high have a diagnosis of depression confirmed based on the DSM-IV criteria.

  15. Number of participants with a recurrent stroke including ischaemic and hemorrhagic strokes

    Time frame: At 6 and 12 months

    Number of participants with a recurrent stroke including ischaemic and hemorrhagic strokes

  16. Number of participants with an acute coronary syndromes

    Time frame: At 6 and 12 months

    Number of participants with an acute coronary syndromes

  17. Number of participants with an Epileptic seizures

    Time frame: At 6 and 12 months

    Number of participants with an epileptic seizures

  18. Number of participants with an episodes of Hyponatraemia

    Time frame: At 6 and 12 months

    Number of participants with an episodes of hyponatraemia (<125 mmol/l)

  19. Number of participants with an upper gastrointestinal bleeding

    Time frame: At 6 and 12 months

    Number of participants with an upper gastrointestinal bleeding

  20. Number of participants with other major bleeds

    Time frame: At 6 and 12 months

    Number of participants with an other major bleeds includes lower GI, extracranial, intracranial but extracerebral

  21. Number of participants with poorly controlled diabetes

    Time frame: At 6 and 12 months

    Number of participants with an poorly controlled diabetes including hyperglycaemia (>22 mmol/l) and hypoglycaemia

  22. Number of participants with falls resulting in injury

    Time frame: At 6 and 12 months

    Number of participants with falls resulting in injury

  23. Number of participants with new fractures

    Time frame: At 6 and 12 months

    Number of participants with new fractures

  24. Fatigue measured with the vitality subscale of the Health Questionnaire

    Time frame: At 6 and 12 months

    Fatigue will be measured with the vitality subscale of the Health Questionnaire, equivalent to SF 36.

  25. Cognition assessed with the Stroke Impact Scale

    Time frame: At 6 and 12 months

    Cognition-the Stroke Impact Scale, which incorporates an assessment of memory and thinking, is used in conjunction with with the Montreal Cognitive Assessment (MoCA)

  26. Health-related quality of life measured with the five-level Euroqol 5D (EQ5D-5 L)

    Time frame: At 6 and 12 months

    Health-related quality of life measured with the five-level Euroqol 5D (EQ5D-5 L).

  27. Cost-effectiveness and cost-utility assessed by measuring costs, survival and health related quality of life (EQ5D)

    Time frame: At 6 and 12 months

    Direct and indirect costs will be estimated at 3-month, 6- month and 1 year. Effects will be measured using survival and EuroQoL 5 Dimensions (EQ5D) scale, which will be estimated into a utility score. The effectiveness measure that will be used for comparison purposes, the quality adjusted life years (QALYs), will be estimated by multiplying the relevant time parameter of the comparison with the estimated utility scores.

    A societal perspective will be adapted for the analysis, and comparison of costs and effects (QALYs) will be conducted for the period of the clinical trial, as well as by adopting a lifetime perspective, where costs and QALYs will be extrapolated beyond the duration of the trial over the expected lifetime of patients. Standard statistical regressions will be used in order to calculate the expected lifetime costs and QALYs.

  28. Physical activity

    Time frame: 1 week, 1 month, 3 months, and 6 months

    Physical activity will be measured using the Saltin-Grimby Physical Activity Level Scale

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Hjärnfonden (The Swedish Brain foundation)
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
  • Stroke-Riksförbundet
  • Swedish Heart Lung Foundation
  • The Swedish Medical Association
  • The Swedish Research Council

Registry information

Official study title

Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke

Acronym: EFFECTS

Important dates

Study start
2014
Primary completion
2020
Study completion
2020
First posted
Feb 17, 2016
Registry last updated
Sep 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.